Hong Kong-listed biotech firm uses AI to produce nano-rockets to deliver life-saving drugs
Culture Index
Score Breakdown
Relevance
14/25
Freshness
25/25
Authority
18/20
Brand Signal
6/15
Depth
4/15
5-Axis Cultural Radar
Shares of METiS TechBio surged 173 per cent on their Hong Kong debut on Wednesday as the AI-driven drug design start-up’s initial public offering drew strong demand from investors amid buoyant sentiment for AI-related stocks in the city. Its stocks first traded at HK$28.68, significantly higher than its offering price of HK$10.50 each. Co-founder and CEO of METiS TechBio, Lai Tsai-Ta, who obtained
